Filters

Atsushi Nohara, Hayato Tada, Masatsune Ogura, Sachiko Okazaki, Koh Ono, Hitoshi Shimano, Hiroyuki Daida, Kazushige Dobashi, Toshio Hayashi, Mika Hori, Kota Matsuki, Tetsuo Minamino, Shinji Yokoyama, Mariko Harada-Shiba

Journal of atherosclerosis and thrombosis 2021;28(7):665-678

Free Full Text

Abstract

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Kenneth Cusi, Naim Alkhouri, Stephen A Harrison, Pascale Fouqueray, David E Moller, Sophie Hallakou-Bozec, Sebastien Bolze, Jean-Marie Grouin, Sophie Jeannin Megnien, Julie Dubourg, Vlad Ratziu

The lancet. Gastroenterology & hepatology 2021;6(11):889-902

Full Text

Abstract

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Muthiah Vaduganathan, Azita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V Madhavan, Benjamin W Van Tassell, David Jimenez, Manuel Monreal, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A Parikh, Deepak L Bhatt, Gregory Y H Lip, Gregg W Stone, Harlan M Krumholz, Peter Libby, Samuel Z Goldhaber, Behnood Bikdeli

Journal of the American College of Cardiology 2021;78(16):1635-1654

Free Full Text

Abstract

Results: 1 – 15 / 18

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Lipid Regulating Agents""[mesh_terms]

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges.

Familial Hypercholesterolemia: JACC Focus Seminar 4/4.

HDL-cholesterol and cardiovascular disease: rethinking our approach.

Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction.

Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial.

How Functional Is Moringa oleifera? A Review of Its Nutritive, Medicinal, and Socioeconomic Potential.

Cardiovascular risk reduction with icosapent ethyl.

Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.

Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing.

Mean common or mean maximum carotid intima-media thickness as primary outcome in lipid-modifying intervention studies.

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.

Homozygous Familial Hypercholesterolemia.

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Results for
""Lipid Regulating Agents""[mesh_terms]